In the pathogenesis of myelofibrosis, as well as of myeloproliferative neoplasms in general, has been studied the role of the deregulated activation of the PI3K/AKT/mTOR pathway, that is involved in the regulation of cell cycle in a broad spectrum of cancers, with a critical role in the cell growth, proliferation, survival and apoptosis. A multicenter, phase 1 / 2 study, involving the centers of Florence, Pavia and Bergamo, was recently conducted to evaluate the safety profile and efficacy of Everolimus (RAD001), a specific m-TOR inhibitor derived from Rapamycin. Everolimus was tested as a single therapeutic agent in a total of 39 patients with myelofibrosis with intermediate or high-risk, both Primary (PMF) and post-polycythemia vera (PPV-MF) and post-essential thrombocythemia (PET-MF): in phase 1 the dose of 10 mg/day was identified as the maximum tolerated dose, then this posology was administred in the phase 2 of the study. In this second phase were enrolled 30 subjects (16 PMF, PPV-8 MF, 6 MF-PET), 21 (70%) on them were JAK2V617F mutated, two had the MPLW515L mutation and one the MPLW515K mutation. Everolimus displayed clinical activity in this group of patients with an acceptable safety profile: in fact responses (complete or partial) were documented in terms of reduction of splenomegaly (44%), resolution of constitutional symptoms (69%), pruritus (80%), anemia (25%), leukocytosis (15%) and thrombocytosis (25%). On the other hand, the haematological toxicity was modest, with 8 cases (27%) of grade 2 or 3 anemia, grade 2 neutropenia in 7%, grade 2 thrombocytopenia in 3% of the patients, all reversible after discontinuation of treatment. Overall, non-haematologic effects of clinical relevance were infrequent, and mainly represented by grade 1-2 stomatitis (70%). This study has provided proof-of-concept that targeting mTOR signaling pathway in myelofibrosis is clinical relevant, suggesting the opportunity of further clinical experimentation with everolimus, either as a single agent perhaps with the use of different drug dosage and time schedules, or in combination with other novel molecules, such as histone deacethylase inhibitors or other immunomodulators.
SUMMARY:
In the pathogenesis of myelofibrosis, as well as of myeloproliferative neoplasms in general, has been studied the role of the deregulated activation of the PI3K/AKT/mTOR pathway, that is involved in the regulation of cell cycle in a broad spectrum of cancers, with a critical role in the cell growth, proliferation, survival and apoptosis. A multicenter, phase 1 / 2 study, involving the centers of Florence, Pavia and Bergamo, was recently conducted to evaluate the safety profile and efficacy of Everolimus (RAD001), a specific m-TOR inhibitor derived from Rapamycin. Everolimus was tested as a single therapeutic agent in a total of 39 patients with myelofibrosis with intermediate or high-risk, both Primary (PMF) and post-polycythemia vera (PPV-MF) and post-essential thrombocythemia (PET-MF): in phase 1 the dose of 10 mg/day was identified as the maximum tolerated dose, then this posology was administred in the phase 2 of the study. In this second phase were enrolled 30 subjects (16 PMF, PPV-8 MF, 6 MF-PET), 21 (70%) on them were JAK2V617F mutated, two had the MPLW515L mutation and one the MPLW515K mutation. Everolimus displayed clinical activity in this group of patients with an acceptable safety profile: in fact responses (complete or partial) were documented in terms of reduction of splenomegaly (44%), resolution of constitutional symptoms (69%), pruritus (80%), anemia (25%), leukocytosis (15%) and thrombocytosis (25%). On the other hand, the haematological toxicity was modest, with 8 cases (27%) of grade 2 or 3 anemia, grade 2 neutropenia in 7%, grade 2 thrombocytopenia in 3% of the patients, all reversible after discontinuation of treatment. Overall, non-haematologic effects of clinical relevance were infrequent, and mainly represented by grade 1-2 stomatitis (70%). This study has provided proof-of-concept that targeting mTOR signaling pathway in myelofibrosis is clinical relevant, suggesting the opportunity of further clinical experimentation with everolimus, either as a single agent perhaps with the use of different drug dosage and time schedules, or in combination with other novel molecules, such as histone deacethylase inhibitors or other immunomodulators.
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